The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of
type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was
treated with fingolimod, another group was given guideline based treatment. The changes of
islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed
.